Huub Schellekens

Huub Schellekens's AcademicInfluence.com Rankings

Huub Schellekens

Biology

#8542

World Rank

#11637

Historical Rank

Immunology

#493

World Rank

#510

Historical Rank

biology Degrees

Download Badge

Biology

Huub Schellekens's Degrees

PhD Immunology University of Amsterdam
Masters Biology University of Amsterdam

Similar Degrees You Can Earn

Best Online Master's in Biology

Why Is Huub Schellekens Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Huub Schellekens's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

γ Interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites (1987) (713)
Structure-Immunogenicity Relationships of Therapeutic Proteins (2004) (547)
Immunogenicity of therapeutic proteins: clinical implications and future prospects. (2002) (505)
Bioequivalence and the immunogenicity of biopharmaceuticals (2002) (498)
The hepatitis delta (δ) virus possesses a circular RNA (1986) (431)
Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. (1986) (328)
TRANSMISSION OF HEPATITIS B FROM HEPATITIS-B-SERONEGATIVE SUBJECTS (1988) (306)
Factors influencing the immunogenicity of therapeutic proteins. (2005) (305)
The Immunogenicity of Polyethylene Glycol: Facts and Fiction (2013) (299)
Safety-related regulatory actions for biologicals approved in the United States and the European Union. (2008) (236)
Immunogenicity of biopharmaceuticals. (2006) (226)
Biosimilar therapeutics—what do we need to consider? (2009) (214)
The purification and characterization of rat gamma interferon by use of two monoclonal antibodies. (1986) (203)
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis (2010) (200)
γ‐interferon treatment inhibits collagen deposition in murine schistosomiasis (1989) (200)
Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. (2006) (197)
Immunological mechanism underlying the immune response to recombinant human protein therapeutics. (2010) (192)
Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. (2014) (186)
Cytokines and the immune response (1996) (159)
Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses (1995) (157)
The hepatitis delta (delta) virus possesses a circular RNA. (1986) (157)
Immunogenicity of recombinant human proteins: causes and consequences (2004) (152)
Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice (2012) (144)
Immunogenicity of Therapeutic Proteins: The Use of Animal Models (2011) (141)
Immunogenicity of therapeutic proteins. (2003) (140)
Structural Characterization and Immunogenicity in Wild-Type and Immune Tolerant Mice of Degraded Recombinant Human Interferon Alpha2b (2005) (135)
Follow-on biologics: challenges of the "next generation". (2005) (133)
Cloning and expression of the chromosomal immune interferon gene of the rat. (1985) (133)
Hepatitis B virus antigens made in microbial cells immunise against viral infection. (1984) (130)
Taking immunogenicity assessment of therapeutic proteins to the next level. (2011) (130)
Micelle-Associated Protein in Epoetin Formulations: A Risk Factor for Immunogenicity? (2003) (121)
Monoclonal antibodies to human immune interferon and their use in a sensitive solid-phase ELISA. (1985) (119)
Hybrid mass spectrometry approaches in glycoprotein analysis and their usage in scoring biosimilarity (2016) (113)
Oxidized and Aggregated Recombinant Human Interferon Beta is Immunogenic in Human Interferon Beta Transgenic Mice (2011) (113)
Immunogenicity of mAbs in non-human primates during nonclinical safety assessment (2013) (108)
Quality of Original and Biosimilar Epoetin Products (2010) (105)
Interchangeability, immunogenicity and biosimilars (2012) (105)
Polyphosphate nanoparticles on the platelet surface trigger contact system activation. (2017) (105)
Clinical comparability and European biosimilar regulations (2010) (103)
Identification and transmission of hepatitis B virus-related variants. (1986) (102)
The therapeutic equivalence of complex drugs. (2011) (101)
The safety of switching between therapeutic proteins (2012) (100)
Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. (2012) (99)
How similar do 'biosimilars' need to be? (2004) (97)
How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider (2013) (95)
How to predict and prevent the immunogenicity of therapeutic proteins. (2008) (92)
Immunologic mechanisms of EPO-associated pure red cell aplasia. (2005) (92)
Iatrogenic meningitis by Streptococcus salivarius following lumbar puncture. (1995) (91)
Aggregated Recombinant Human Interferon Beta Induces Antibodies but No Memory in Immune-Tolerant Transgenic Mice (2010) (89)
Biosimilar Epoetins: An Analysis Based on Recently Implemented European Medicines Evaluation Agency Guidelines on Comparability of Biopharmaceutical Proteins (2005) (88)
Pure red cell aplasia induced by erythropoiesis-stimulating agents. (2008) (87)
Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis (2005) (86)
Health risks of genetically modified foods (1999) (82)
On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. (2010) (79)
Immunological Risk of Injectable Drug Delivery Systems (2009) (78)
The Cost‐Effectiveness of Drug Regulation: The Example of Thorough QT/QTc Studies (2012) (77)
Influence of interferon preparations on the proliferative capacity of human and mouse bone marrow cells in vitro. (1978) (75)
Eprex-associated pure red cell aplasia and leachates (2006) (75)
Good laboratory practice for clinical next-generation sequencing informatics pipelines (2015) (74)
When biotech proteins go off-patent. (2004) (72)
Glomerular mesangial cells in local inflammation. Induction of the expression of MHC class II antigens by IFN-gamma. (1989) (72)
Development of a Transgenic Mouse Model Immune Tolerant for Human Interferon Beta (2005) (70)
Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene. (2012) (67)
Antibodies against Erythropoietin and Other Protein‐Based Therapeutics: An Overview (2005) (65)
Antiviral effect of interferon in vivo may be mediated by the host (1979) (63)
The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development. (2003) (60)
IMPACT OF CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGEN EXPRESSION ON THE IMMUNOGENIC POTENTIAL OF ISOLATED RAT VASCULAR ENDOTHELIAL CELLS (1987) (60)
'Biogenerics': the off-patent biotech products. (2002) (60)
Interferon Beta: From Molecular Level to Therapeutic Effects. (2016) (58)
Immunogenicity of bone morphogenetic proteins. (2009) (57)
Safety and efficacy of biosimilars in oncology. (2016) (56)
The first biosimilar epoetin: but how similar is it? (2008) (56)
Erythropoietin-Associated PRCA: Still an Unsolved Mystery (2006) (55)
Conditional Approval and Approval Under Exceptional Circumstances as Regulatory Instruments for Stimulating Responsible Drug Innovation in Europe (2010) (51)
Different Pharmaceutical Products Need Similar Terminology (2013) (51)
Protective immunisation against hepatitis B with an internal antigen of the virus (1987) (50)
Comparative antiviral efficiency of leukocyte and bacterially produced human α-interferon in rhesus monkeys (1981) (50)
Immunogenicity of rDNA-derived pharmaceuticals. (2002) (49)
The ability of animal studies to detect serious post marketing adverse events is limited. (2012) (49)
Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies (2019) (48)
Isolation and characterization of monoclonal antibodies directed to rat interferon-gamma. (1989) (47)
Tumour necrosis factor α, interferon γ and interferon β exert antiviral activity in nervous tissue cells (1991) (47)
Induction of Natural Killer Cell Activity and Allocytotoxicity in Human Peripheral Blood Lymphocytes after Mixed Lymphocyte Culture (1981) (47)
Towards a sustainable system of drug development. (2014) (46)
Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference (2005) (45)
Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis (2004) (45)
Assessing the bioequivalence of biosimilars The Retacrit case. (2009) (45)
Neutralising antibodies to interferon β in multiple sclerosis (2007) (42)
Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta. (2010) (42)
Reduced synthesis of pp60src and expression of the transformation-related phenotype in interferon-treated Rous sarcoma virus-transformed rat cells (1983) (41)
The immunogenicity of biopharmaceuticals (2003) (41)
Cloning, expression, and purification of rat IFN-gamma. (1986) (40)
Aggregation and Immunogenicity of Therapeutic Proteins (2010) (40)
FIBROBLAST INTERFERON IN HBsAg-POSITIVE CHRONIC ACTIVE HEPATITIS (1977) (38)
Making individualized drugs a reality (2017) (38)
Production and initial characterization of rat interferon. (1980) (38)
Suppression and augmentation of rat adjuvant arthritis with monoclonal anti-interferon-gamma antibody. (1989) (37)
An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products. (2011) (36)
Animal models in AIDS (1990) (36)
The value of non-human primates in the development of monoclonal antibodies (2013) (34)
Assays for antibodies to human interferon-alpha: the need for standardization. (1997) (33)
Structure and expression in Escherichia coil of a cloned rat interferon-α gene (1984) (33)
A standardised framework to identify optimal animal models for efficacy assessment in drug development (2018) (32)
Plasmodium falciparum: studies on mature exoerythrocytic forms in the liver of the chimpanzee, Pan troglodytes. (1990) (31)
Biosimilar therapeutic agents: issues with bioequivalence and immunogenicity (2004) (31)
Longitudinal analysis of hepatitis C virus infection and genetic drift of the hypervariable region. (1994) (30)
Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine). (1990) (30)
Anti-cytokine autoantibodies: Epiphenomenon or critical modulators of cytokine action (1997) (30)
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. (2007) (30)
Effect of treatment with interferon and cyclophosphamide on the growth of a spontaneous liposarcoma in rats (1983) (29)
Hepatitis delta virus cDNA sequence from an acutely HBV‐infected chimpanzee: Sequence conservation in experimental animals (1991) (28)
Are we ready to close the discussion on the interchangeability of biosimilars? (2019) (28)
Are some animal models more equal than others? A case study on the translational value of animal models of efficacy for Alzheimer''s disease. (2019) (28)
Double‐blind study of interferon administration in renal transplant recipients (1978) (27)
The immunogenicity of therapeutic proteins. (2010) (27)
Complete nucleotide sequence and viral envelope protein expression of a hepatitis B virus DNA derived from a hepatitis B surface antigen-seronegative patient. (1993) (26)
Circulating interferon in rabbits and monkeys after administration of human gamma interferon by different routes. (1983) (26)
How Bio-questionable are the Different Recombinant Human Erythropoietin Copy Products in Thailand? (2014) (26)
Relationship between biopharmaceutical immunogenicity of epoetin alfa and pure red cell aplasia (2003) (25)
Differential sensitivity of Rauscher murine leukaemia virus (MuLV-R) to interferons in two interferon-responsive cell lines. (1976) (25)
The Pharmacokinetic and Biological Activity Profile of Dexamethasone Targeted to Sinusoidal Endothelial and Kupffer Cells (2003) (25)
Effect of Treatment Regimen on the Immunogenicity of Human Interferon Beta in Immune Tolerant Mice (2013) (25)
Influence of input multiplicity of infection on the antiviral activity of interferon. (1980) (24)
Biosimilar monoclonal antibodies: the scientific basis for extrapolation (2015) (24)
The Rebif® New Formulation Story (2007) (24)
Influence of Aggregation and Route of Injection on the Biodistribution of Mouse Serum Albumin (2014) (24)
Differential effects of fibroblast and leucocyte interferon in HBsAg positive chronic active hepatitis (1979) (22)
Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab. (2013) (22)
Effect of recombinant interferon gamma and interleukin-2 and of a monoclonal antibody against interferon gamma on the rat immune response against heart allografts. (1991) (21)
Recombinant human erythropoietins, biosimilars and immunogenicity. (2008) (21)
Contribution of animal studies to evaluate the similarity of biosimilars to reference products. (2015) (21)
Antagonistic effects of gamma interferon and steroids on tissue antigenicity (1986) (21)
Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products. (2016) (21)
Effective pharmaceutical regulation needs alignment with doctors. (2012) (21)
Prevention of vaccinia lesions in Rhesus monkeys by human leucocyte and fibroblast interferon. (1980) (20)
Chapter 6 Structural characterization and immunogenicity in wildtype and immune tolerant mice of degraded recombinant human interferon alpha 2 b (2005) (20)
Appropriate Conditions for Maintenance of Chimpanzees in Studies With Blood‐Borne Viruses: An Epidemiologic and Psychosocial Perspective (1989) (19)
Immunogenicity of Recombinant Human Interferon Beta-1b in Immune-Tolerant Transgenic Mice Corresponds with the Biophysical Characteristics of Aggregates. (2016) (19)
How institutional logics hamper innovation: The case of animal testing (2017) (18)
The constrained prescription, interchangeability and substitution of biosimilars (2015) (18)
Neonatal Host Defense Mechanisms against Listeria monocytogenes Infection: The Role of Lipopolysaccharides and Interferons (1989) (18)
A novel oral iron-complex formulation: Encapsulation of hemin in polymeric micelles and its in vitro absorption. (2016) (18)
Iron nanomedicines induce Toll-like receptor activation, cytokine production and complement activation. (2017) (17)
Label-free glycoprofiling with multiplex surface plasmon resonance: a tool to quantify sialylation of erythropoietin. (2015) (17)
Hemoglobin Variability in Patients with Chronic Kidney Disease in the Netherlands (2009) (17)
Rat cytomegalovirus: induction of and sensitivity to interferon. (1983) (17)
Thirty years of preclinical safety evaluation of biopharmaceuticals: did scientific progress lead to appropriate regulatory guidance? (2012) (17)
Chemical inactivation of hepatitis B virus: the effect of disinfectants on virus-associated DNA polymerase activity, morphology and infectivity. (1983) (17)
The immunogenicity of therapeutic proteins and the Fabry antibody standardization initiative. (2008) (16)
Effect of Arginine on Pre-nucleus Stage of Interferon Beta-1b Aggregation (2014) (16)
Antibody Response Against Betaferon® in Immune Tolerant Mice: Involvement of Marginal Zone B-cells and CD4+ T-cells and Apparent Lack of Immunological Memory (2012) (16)
B-1 cells and naturally occurring antibodies: influencing the immunogenicity of recombinant human therapeutic proteins? (2009) (16)
Development of a transgenic mouse model to study the immunogenicity of recombinant human insulin. (2014) (15)
Treatment of Juvenile Laryngeal Papillomatosis with Two Types of Interferon (1982) (15)
Mechanism of escape of exoerythrocytic forms (EEF) of malaria parasites from the inhibitory effects of interferon-gamma. (1987) (15)
The effects of dodecyl maltoside and sodium dodecyl sulfate surfactants on the stability and aggregation of recombinant interferon Beta-1b. (2014) (15)
Correction: A standardised framework to identify optimal animal models for efficacy assessment in drug development (2019) (15)
The Cost‐Effectiveness of Periodic Safety Update Reports for Biologicals in Europe (2013) (14)
Vascular endothelium in allograft rejection. (1988) (14)
Human interferon does not protect cowpea plant cell protoplasts against infection with alfalfa mosaic virus. (1985) (14)
Simple method for measuring growth inhibition by interferon of cells in monolayer. (1980) (14)
Baculovirus-directed high level expression of the hepatitis delta antigen in Spodoptera frugiperda cells. (1991) (14)
Oromucosal interferon therapy: relationship between antiviral activity and viral load. (2001) (14)
Antiviral activity of interferon in rats and the effect of immune suppression. (1984) (14)
Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera. (2008) (13)
In vivo antiproliferative effects of gamma-interferon and tumor necrosis factor alpha in a rat renal cell carcinoma model system. (1990) (13)
Treatment of Juvenile laryngeal papillomatosis with two types of interferon. (1982) (13)
Reassessments of ESAs for cancer treatment in the US and Europe. (2010) (13)
Isolation of parainfluenza virus type 3 from cerebrospinal fluid. (1992) (13)
Reaction to the paper: Interaction of Polysorbate 80 with Erythropoietin: A Case Study in Protein–Surfactant Interactions (2006) (13)
Chimpanzees and AIDS research (1988) (13)
Detection of Chlamydia trachomatis in clinical specimens Comparison of culture, direct antigen detection, DNA probe hybridization and PCR (1994) (13)
Recombinant interferon-γ applied to the brain ventricular system protects rats against pseudorabies (1990) (13)
The Chimpanzee as a Model to Test the Side Effects of Human Interferons (1984) (13)
Today’s Challenges in Pharmacovigilance (2011) (12)
Serum capacity to inhibit reverse transcriptase in vitro distinguishes HIV-1 infection from HIV-2 or SIV infection. (1989) (12)
Pharmacokinetic Studies with Human and Rat Interferons-γ in Different Species (1986) (12)
The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals (2012) (12)
The risk-based approach to ATMP development - generally accepted by regulators but infrequently used by companies. (2013) (12)
Antiviral and side effects of interferons produced by recombinant DNA techniques as tested in rhesus monkeys. (1982) (12)
Liposome‐targeted recombinant human acid sphingomyelinase: Production, formulation, and in vitro evaluation (2019) (12)
Impact of Biosimilar Insulins on Clinical Practice (2014) (11)
Natural antibodies against bone morphogenic proteins and interferons in healthy donors and in patients with infections linked to type-1 cytokine responses. (2011) (11)
Hepatitis C virus antibody detection by a line ImmunoAssay and (near) full length genomic RNA detection by a new RNA‐capture polymerase chain reaction (1992) (11)
The Biology of the Interferon System 1986 (1987) (11)
The sponsored pandemic of the Mexican flu? (2011) (11)
Tradition, not science, is the basis of animal model selection in translational and applied research. (2020) (10)
Antiviral activity of human leucocyte interferon in rhesus monkeys and marmosets (1981) (10)
Cloning, expression, and purification of rat IFN-alpha 1. (1986) (10)
The protection of chimpanzees against hepatitis B viral infection using a recombinant yeast-derived hepatitis B surface antigen. (1987) (10)
A sensitive two-site enzyme immunoassay for the detection of rat interferon-gamma in biological fluids. (1990) (10)
Antiviral activity of recombinant rat interferon gamma in immunologically impaired and immunosuppressed rats. (1988) (10)
Phytohaemagglutinin-induced susceptibility to lysis by natural and activated killer cells of autologous allogeneic and xenogeneic target cells. (1982) (10)
A phase I clinical tolerance study of rDNA alpha 2 human interferon in patients with non-reticuloendothelial system malignancies. (1983) (9)
Biosimilars or semi-similars? (2015) (9)
Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product (2018) (9)
In vivo immune stimulation by interferon during viral infection. (1981) (9)
Differences Between Post-Authorization Adverse Drug Reactions of Biopharmaceuticals and Small Molecules (2013) (9)
Drug regulatory systems must foster innovation. (2011) (9)
Letter 2: Equivocal role of micelles in Eprex adverse events (2003) (9)
Erythropoietic proteins and antibody-mediated pure red cell aplasia: a potential role for micelles. (2004) (9)
Value for money of drug regulation (2012) (8)
Erratum: Making individualized drugs a reality (2017) (8)
Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have? (2006) (8)
The influence of emetine on the induction of interferon by poly-I: poly-C in Swiss mice. (1975) (8)
Tumour necrosis factor-alpha, interferon-gamma and interferon-beta exert antiviral activity in nervous tissue cells. (1991) (8)
Prophylactic use of interferon in renal allograft recipients. (1979) (8)
Development of ADA against recombinant human interferon beta in immune tolerant mice requires rapid recruitment of CD4⁺ T cells, induces formation of germinal centers but lacks susceptibility for (most) adjuvants. (2015) (8)
A Cohort Study Exploring Determinants of Safety-Related Regulatory Actions for Biopharmaceuticals (2012) (8)
Clinical and immunologic staging of feline immunodeficiency virus (FIV) infection. (1990) (7)
Biological effect of interferon-gamma during the course of experimental infection of rat by Schistosoma mansoni. (1990) (7)
Biosimilars need comparative clinical data. (2011) (7)
Neonatal Listeria monocytogenes Infection is Refractory to Interferon (1991) (7)
A modified immune tolerant mouse model to study the immunogenicity of recombinant human interferon beta. (2014) (7)
Willingness to Pay for Adverse Drug Event Regulatory Actions (2011) (7)
The effects of recombinant and natural human interferons in vaccinia virus infected rhesus monkeys. (1985) (7)
Comparison of drug efficacy in two animal models of type 2 diabetes: A systematic review and meta-analysis. (2020) (6)
Protection of Rats against Pseudorabies Virus Infection by γ-Interferon (1989) (6)
Efficacy and toxicity of interferons in experimental animals. (1987) (6)
The effect of recombinant human interferon α BD compared to interferon α 2b on SIV infection in rhesus macaques (1996) (6)
Leukocyte binding and Ia-expression in vascular endothelium. (1987) (6)
An Albumin-Free Formulation for Escherichia coli-Derived Interferon Beta-1b with Decreased Immunogenicity in Immune Tolerant Mice. (2016) (6)
Biopharmaceutical molecules are not created equally (2002) (6)
Immunogenicity of biopharmaceuticals. The European perspective. (2003) (5)
Additive and synergistic antitumor effects with toremifene and interferons. (1990) (5)
Lesson Learned from Eprex-Associated Pure Red Cell Aplasia (2007) (4)
Growth inhibition and eicosanoid metabolism in the R3230AC mammary adenocarcinoma by interferon. (1986) (4)
Relationship between the cellular expression of the antiviral and anticellular activities of interferon. (1981) (4)
Pathways in the Drug Development for Alzheimer’s Disease (1906-2016): A Bibliometric Study (2020) (4)
Biological and molecular characterization of the hepatitis delta virus. (1987) (4)
Neutralizing antibodies to interferon beta in patients with multiple sclerosis: scientific background and clinical implications (2004) (4)
The clinical value of interferon--a critical appraisal. (1981) (3)
Reply to In support of the European Union biosimilar framework (2012) (3)
Monkeys are insensitive to pyrogenic effects of human α-interferons (reply) (1982) (3)
Immunogenicity of Antibody Therapeutics (2008) (3)
Erratum: Making individualized drugs a reality (2017) (3)
Structure and expression in Escherichia coli of a cloned rat interferon-alpha gene. (1984) (3)
Immunogenicity of Therapeutic Proteins and the Assessment of Risk (2010) (3)
The Cost-Effectiveness of Periodic Safety Update Reports (PSURS) for Biologicals in Europe (2013) (3)
THE TOXICITY OF HUMAN INTERFERONS IN NONHUMAN PRIMATES (1982) (3)
The biology of the interferon system 1985 : proceedings of the 1985 TNO-ISIR Meeting on the Interferon System, held in Clearwater Beach, Florida, USA on 13-18 October, 1985 (1986) (3)
Production, purification, and characterization of rat interferon from transformed rat cells. (1986) (3)
[Overregulation and unnecessary animal testing: requirements for market approval of biopharmaceuticals too rigid]. (2012) (2)
Approved in the United States and the European Union Safety-Related Regulatory Actions for Biologicals (2008) (2)
The biology of the interferon system 1984 : proceedings of the 1984 TNO-ISIR Meeting on the Interferon System, held in Heidelberg, Federal Republic of Germany on 21-25 October, 1984 (1985) (2)
Protection of rats against pseudorabies virus infection by gamma-interferon. (1989) (2)
Post-innovation innovation of medicinal products. (2011) (2)
The contribution of periodic safety reports (PSURs) to safety related regulatory actions of biopharmaceuticals (2010) (2)
Immunogenicity of therapeutique proteins: Clinical implication and futur prospects. Editorial comment (2002) (2)
Prophylaxis and therapy of HBsAg positive hepatitis. (1979) (2)
The effect of recombinant human interferon alpha B/D compared to interferon alpha 2b on SIV infection in rhesus macaques. (1996) (2)
Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. (2007) (2)
Between clones and clinic. (1988) (2)
Differential effects of exogenous fibroblast and leucocyte interferon in HBsAg chronic hepatitis (1978) (2)
Evaluation of the suitability of a Sprague Dawley rat model to assess intravenous iron preparations. (2018) (2)
The biology of the interferon system : proceedings of the International Meeting on the Biology of the Interferon System held in Rotterdam, the Netherlands, on 21-24 April, 1981 (1981) (2)
Efficacy and safety of orally/sublingually, intranasally, and intraperitoneally administered recombinant murine interferon in the treatment of murine encephalomyocarditis virus. (2001) (2)
Animal models in AIDS: International TNO meeting, Maastricht, Netherlands, 23-26 October 1989. (1990) (1)
Interferon Studies in Non-Human Primates (1988) (1)
EFFECT OF MULTIPLICITY OF INFECTION ON THE ANTIVIRAL ACTION OF INTERFERON IN VITRO (1980) (1)
Antitumor Effects of Rat Rec.Ifn-γ in Rats Bearing Transplantable Rat Tumors (1987) (1)
Modulation of the immune response by interferon gamma administration in a rat cardiac allograft model. (1989) (1)
Non Biologic Complex Drug Concept: Experiences with Iron Sucrose and LowMolecular Weight Heparin (2014) (1)
Feasibility Study for Bedside Production of Recombinant Human Acid α-Glucosidase: Technical and Financial Considerations. (2020) (1)
Cytokine Yearbook Volume 1 (1996) (1)
Pharmacokinetic studies with human and rat interferons-gamma in different species. (1986) (1)
Erythropoiesis-stimulating Agents – Present and Future (2006) (1)
Animal models in interferon research: Some current trends (1989) (1)
AIDS: Questions and answers: by V.G. Daniels Cambridge Medical Books, Cambridge, 1986 95 pages (1986) (1)
Biomarkers for the Immunogenicity of Therapeutic Proteins and Its Clinical Consequences (2010) (1)
Role of interferon-γ on the in vivo expression of functional interleukin-2 receptors by murine macrophages (1991) (1)
Concomitant enhancement of a cytoskeleton-associated 76,000-dalton protein and inhibition of fluid-phase pinocytosis by interferon-alpha in Fujinami sarcoma virus-transformed rat 3Y1 cells. (1986) (0)
Effective antiviral prophylaxis with human interferons in a rhesus monkey model. (1981) (0)
Implementation of in vitro replacement technologies in regulatory drug testing - An innovation systems perspective (2011) (0)
The future of non-human primates in the development of biopharmaceuticals (2012) (0)
Differences Between Post-Authorization Adverse Drug Reactions of Biopharmaceuticals and Small Molecules (2013) (0)
The quality of post marketing surveillance of biotech drugs (2008) (0)
Antibody Assays in Animal Research (2011) (0)
Different Pharmaceutical Products Need Similar Terminology (2013) (0)
High dose interferon alpha B/D in patients with chronic hepatitis B. (1996) (0)
Immune mechanisms underlying immunogenicity of aggregated recombinant human interferon alpha‐2a in immune tolerant mice (2013) (0)
Opening Keynote and Introductory Session (2010) (0)
Interferon as an Antiviral Agent (1988) (0)
The biology of the interferon system 1983 : proceedings of the Second International TNO Meeting on the Biology of the Interferon System, held in Rotterdam, The Netherlands, on 18-22 April, 1983 (1983) (0)
The value of non-human primates in the development of therapeutic monoclonal antibodies (2011) (0)
Interferons, properties and applications (1980) (0)
[Virus infections in kidney transplant patients]. (1977) (0)
The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals (2012) (0)
Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (2007) (0)
Transition towards replacing animal tests in safety assessment of cosmetics and chemicals: a combined TIS-MLP framework (2012) (0)
The outcome of psur assessments of biopharmaceuticals (2011) (0)
Review of: "Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution" (2022) (0)
Antibodies in Cytokines (1997) (0)
Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product (2018) (0)
Evolution of the immune system and invertebrate immunity (PP-009) (2010) (0)
Factors inhibiting IFN activity (1996) (0)
The challenge of regulating biologicals: the PRCA controversy and the creation of the European biosimilar regulatory framework (2013) (0)
Rigaud and Schmincke Types of Lymphoepithelioma (2011) (0)
Infectious hepatitis B virus from cl nucleotide sequence (chimpanzee transfection/recombinant hepatitis B virus DNA/risk a: (2016) (0)
Effect of Arginine on Pre-nucleus Stage of Interferon Beta-1b Aggregation (2014) (0)
A comparison of post-authorization adverse events of biopharmaceuticals and small molecules within the same anatomical therapeutic chemical class (2012) (0)
Antibodies in Cytokines: The concerted action on the antigenicity of rDNA derived pharmaceuticals (1997) (0)
Reply to: Equivocal role of micelles in Eprex adverse events (2003) (0)
Whatever happened to acid rain (2004) (0)
Safety Warnings Issued for Biotechnology Derived Pharmaceuticals Approved Since 1995 (2007) (0)
The Antigenicity of Recombinant‐DNA‐derived Pharmaceuticals (1997) (0)
How Bio-questionable are the Different Recombinant Human Erythropoietin Copy Products in Thailand? (2013) (0)
Realising the Full Potential of Biosimilars: Interviews with Three Key Opinion Leaders (2018) (0)
Understanding transition dynamics using a combined TIS-MLP approach (2012) (0)
[Interferon and virus infections]. (1977) (0)
Interferons: past, present and future (1985) (0)
A future for exogenous interferon therapy? (1978) (0)
Efficacy of a novel interferon alpha B/D, given in high dose. Monitored by quantitative HBeAg, HBsAg and HBV-DNA in patients with chronic hepatitis B. (1996) (0)
Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs (2023) (0)
Poster Presentations (2007) (0)
Spending on BSE research (1996) (0)
The cost-effectiveness of drug regulation (2008) (0)
Protein quality testing in the era of personalized medicine. (2020) (0)
How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider (2013) (0)
The transition to a sustainable system of drug development requires reformation of the regulatory and patent systems, and a shift of responsibility to open-access discovery and clinical evaluation of innovative drugs to the public sector. (2014) (0)
A divided INN crowd (2014) (0)
The risk-based approach to ATMP development – Generally accepted by regulators but infrequently used by companies Regulatory Toxicology and Pharmacology (2013) (0)
Tolerance and Antiviral Effects of High-Dose Interferon-α B/D in Patients with Chronic Hepatitis B (1998) (0)
The development and validation of immune tolerant mouse models to measure and predict the immunogenicity of monoclonal antibody (MAb) therapeutics (2007) (0)
The Immunogenicity of Polyethylene Glycol: Facts and Fiction (2013) (0)
Development of Rebif (R) New Formulation for MS treatment: consolidated results from preclinical and phase I studies (2007) (0)
Understanding the lengthy process to replace the draize test (2012) (0)
The Biology of the interferon system 1986 : proceedings of the 1986 ISIR-TNO meeting on the interferon system, 7-12 September 1986, Dipoli Congress Center, Espoo, Finland (1987) (0)
Is it true what they say about interferon? (1979) (0)
Safety and efficacy of biosimilar epoetins. (2004) (0)
Effect of Treatment Regimen on the Immunogenicity of Human Interferon Beta in Immune Tolerant Mice (2013) (0)
Antibody Response Against Betaferon® in Immune Tolerant Mice: Involvement of Marginal Zone B-cells and CD4+ T-cells and Apparent Lack of Immunological Memory (2012) (0)
Responsible early diagnostics for Alzheimer's disease (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Huub Schellekens?

Huub Schellekens is affiliated with the following schools:

Utrecht University

Huub Schellekens's Academic­Influence.com Rankings